Corbus Pharmaceuticals (NASDAQ:CRBP) Announces Earnings Results

Posted by Brenda Bartman on May 13th, 2026

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($1.23) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.03, FiscalAI reports.

Corbus Pharmaceuticals Stock Performance

Shares of NASDAQ CRBP traded up $0.01 during trading on Wednesday, hitting $11.44. The company had a trading volume of 24,416 shares, compared to its average volume of 218,316. Corbus Pharmaceuticals has a 52 week low of $6.72 and a 52 week high of $20.56. The business’s 50-day moving average is $9.70 and its 200 day moving average is $9.70. The company has a market cap of $202.86 million, a P/E ratio of -1.91 and a beta of 2.68.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CRBP. Oppenheimer boosted their price objective on Corbus Pharmaceuticals from $53.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, March 10th. Guggenheim began coverage on shares of Corbus Pharmaceuticals in a research report on Wednesday, April 29th. They issued a “buy” rating and a $45.00 target price for the company. Wall Street Zen raised Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Monday, April 20th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $33.00 price objective on shares of Corbus Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, Corbus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $42.67.

Get Our Latest Stock Analysis on Corbus Pharmaceuticals

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of hedge funds have recently modified their holdings of CRBP. Orbimed Advisors LLC lifted its holdings in shares of Corbus Pharmaceuticals by 36.3% during the fourth quarter. Orbimed Advisors LLC now owns 1,597,287 shares of the biopharmaceutical company’s stock valued at $13,002,000 after purchasing an additional 425,000 shares during the last quarter. Prosight Management LP increased its stake in Corbus Pharmaceuticals by 99.1% in the 4th quarter. Prosight Management LP now owns 683,872 shares of the biopharmaceutical company’s stock worth $5,567,000 after purchasing an additional 340,472 shares in the last quarter. Vanguard Group Inc. increased its stake in Corbus Pharmaceuticals by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 612,030 shares of the biopharmaceutical company’s stock worth $7,742,000 after purchasing an additional 12,535 shares in the last quarter. Armistice Capital LLC raised its holdings in Corbus Pharmaceuticals by 179.2% during the 4th quarter. Armistice Capital LLC now owns 536,000 shares of the biopharmaceutical company’s stock worth $4,363,000 after buying an additional 344,000 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in Corbus Pharmaceuticals by 230.5% during the fourth quarter. Renaissance Technologies LLC now owns 354,300 shares of the biopharmaceutical company’s stock valued at $2,884,000 after buying an additional 247,100 shares in the last quarter. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Company Profile

(Get Free Report)

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.